Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer — An ASCO Reading Room selection by MedPage Today Staff November 7, 2022 • 1 min read ...

A total of 2128 patients were included in the analysis — 563 (27%) who received enfortumab vedotin plus pembrolizumab, 814 (38%) who received enfortumab vedotin alone, and 751 (35%) who received ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

A target of enfortumab vedotin is Nectin-4, a molecule ordinarily expressed in skin, as well as various internal structures of the body. High expression of Nectin-4 is seen with many cancers.

Enfortumab vedotin, an antibody–drug conjugate directed against nectin-4, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, have individually been associated with a survival benefit in ...

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) ...

The recommended enfortumab vedotin dose with pembrolizumab is 1.25 mg/kg IV, up to a maximum of 125 mg, on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity.

Nectin-4, the target structure of EV, is localized on chromosome 1q23.3. This gene segment is increased in about 20-25 percent of urothelial carcinomas, which is referred to as amplification.

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to ...

Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma New study identifies NECTIN4 amplification as a promising biomarker ...

In addition, enfortumab vedotin plus pembrolizumab is currently under investigation in two randomized phase III studies in muscle-invasive bladder cancer (EV-303/KN-905, ClinicalTrials.gov identifier: ...